Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 4/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | SLC27A1 | Q6PCB7 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3080481 | 0.90 | PRKDC (0.50) | CNR2JAK1 | |
| SCHEMBL3080789 | 0.90 | FYN (0.48) | ALDH1A1L3MBTL1SLC27A1KDM4E | |
| SCHEMBL3084701 | 0.82 | MCHR1 (0.47) | — | |
| SCHEMBL3077086 | 0.79 | CNR2 (0.44) | CNR2KITCNR1JAK1SLC27A1 | |
| SCHEMBL5384466 | 0.76 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1KDM4ENPC1RAB9A | |
| SCHEMBL3089794 | 0.76 | USP7 (0.44) | ALDH1A1L3MBTL1KDM4ENPC1RAB9A | |
| SCHEMBL28570789 | 0.75 | HSP90AA1 (0.47) | ALDH1A1L3MBTL1KDM4ENPC1RAB9A | |
| SCHEMBL3076680 | 0.75 | PTGS1 (0.49) | CNR2ALDH1A1L3MBTL1SLC27A1KDM4E | |
| SCHEMBL3070139 | 0.74 | KDM4E (0.47) | ALDH1A1L3MBTL1KDM4ENPC1RAB9A | |
| SCHEMBL3083714 | 0.73 | PRKDC (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227880-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-09-09 | — | — | US | disclosed |
| EP-1984375-A2 | CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007087548-A9 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007087548-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227880-A1 | CHEMICAL COMPOUNDS | CYP3A5, SLC10A1, ABCB11 | CNR2 589/4885ALDH1A1 210/4885L3MBTL1 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.